Drug Profile
602 - 3SBio
Latest Information Update: 25 Jul 2022
Price :
$50
*
At a glance
- Originator 3SBio
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer
Most Recent Events
- 25 Jul 2022 602 is still in phase I trials for Colorectal cancer (Late-stage disease, Metastatic disease) in China (Parenteral) (3SBio pipeline, July 2022)
- 30 Mar 2021 3SBio completes a phase I trial in Colorectal cancer in China prior to March 2021
- 16 Sep 2019 Phase-II clinical trials in Colorectal cancer (Late-stage disease, Metastatic disease) in China (Parenteral) (3SBio pipeline, September 2019)